Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate

Lage MJ, Gross GN, Brewster C, Spalitto A

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19669630

DOI
10.1007/s12325-009-0056-z

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Androstadienes /economics; Anti-Asthmatic Agents /economics; Anti-Inflammatory Agents /economics; Asthma /drug therapy /economics; Beclomethasone /economics; Cost of Illness; Drug Costs /statistics & numerical data; Drug Therapy, Combination; Emergency Service, Hospital /economics; Female; Fluticasone; Health Care Costs /statistics & numerical data; Hospitalization /economics; Humans; Insurance Claim Reporting /economics; Male; Medication Adherence /statistics & numerical data; Middle Aged; Multivariate Analysis; Outcome Assessment (Health Care) /organization & administration; Patient Selection; Regression Analysis; Retrospective Studies; United States

AccessionNumber
22010000505

Date bibliographic record published
04/08/2010